Walking with modafinil and its use in diplegic cerebral palsy: retrospective review.
A retrospective review of pediatric patients with spastic cerebral palsy was undertaken at Texas Tech University Health Sciences Center covering a period from January 1, 2000, until December 31, 2003. One hundred twenty pediatric patients were identified in the Texas Tech University Health Sciences Center child neurology clinic with spastic cerebral palsy. Fifty-nine patients of this group received modafinil treatment for cerebral palsy. Twenty-nine of the 59 patients were noted to have an improving gait on modafinil. Six of these modafinil-treated patients improved from no ambulation or only assisted ambulation to unassisted ambulation. This varied from taking a few steps without holding on to walking down the hall without assistance. Two patients with spastic diplegia secondary to prematurity have had a dramatic improvement in gait during the first 6 months after starting modafinil. Two other patients with spastic diplegia not included in this group of six patients taught themselves to stand up and walk while in water unassisted. During this same time period, only three non-modafinil-treated patients with mild cerebral palsy were noted with gait improvements, but not to the dramatic extent of the modafinil-treated group. A nonambulatory 5-year-old child, who presented for a requested wheelchair prescription because the mother had given up all hope of her child ever walking, is now taking independent steps unassisted after starting modafinil. Modafinil, a central nervous system stimulant, appears to improve tone and ambulation in spastic diplegic cerebral palsy.
Hurst
Daniel L
DL
Department of Neuropsychiatry, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA. daniel.hurst@ttuhsc.edu
Lajara-Nanson
Walter A
WA
Lance-Fish
Margie E
ME
D000293:Adolescent; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D020233:Gait Disorders, Neurologic / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000077408:Modafinil; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D016138:Walking / Q000502:physiology*
D001559:Benzhydryl Compounds; D018696:Neuroprotective Agents; D000077408:Modafinil